Pre-clinical work in MYC amplified oesophageal cancer cell lines demonstrating a sensitivity to the BTK/HER2 inhibitor ibrutinib.76 Leading on from this, ibrutinib is currently being evaluated in the treatment of c-MYC and HER2 amplified gastro-oesophageal cancer.77 An alternative therapeutic approach targeting c-MYC mutant malignancies is to reduce the levels of the c-MYC protein, with a phase I study currently evaluating WB100, an oral molecule glue that pre-clinically selectively degraded c-MYC protein over other proteins.78,79. This evidence concerns the gene ERBB2 and carcinoma of esophagus.